CORONARY BIFURCATION DISEASE
Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third has a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.
TRYTON SIDE BRANCH STENT
The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-ZONE™ technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.
RANDOMIZED TRYTON IDE STUDY
The landmark Tryton IDE study was a multi-national randomized trial that compared a Tryton stent in the side branch vs. the use of balloon angioplasty in the side branch, with both arms of the trial utilizing a standard drug eluting stent in the main vessel. The study, which was the first and only randomized IDE clinical trial of a bifurcation stent, enrolled over 700 patients from up to 75 centers in North America, Europe and Israel. Martin Leon, M.D. (Columbia University, New York) served as principal investigator for the study and Patrick Serruys, M.D., PhD. (Thoraxcenter, Rotterdam) lead the IVUS and three-dimensional angiographic analyses.
TRYTON MEDICAL, INC.
Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of medicine at Dartmouth Medical School/Dartmouth- Hitchcock Medical Center) and Dan Cole to develop stents for the definitive treatment of bifurcation lesions. Privately held, Tryton is backed by PTV Sciences, RiverVest Venture Partners, Spray Venture Partners and the 3×5 Special Opportunity Fund.
Please follow the company on Twitter at @TrytonMedical1.